Johanna Olweus

Oslo University Hospital — Norway

Medicine · Health Sciences

32h-index5.4kcitations100works4.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

CAR-T cell therapy research(40), Immune Cell Function and Interaction(38), Immunotherapy and Immune Responses(36), Cancer Immunotherapy and Biomarkers(20), T-cell and B-cell Immunology(19)

Publications100 total

Immediate transcriptional changes initiated by direct cell-cell contact between cytotoxic T cells and cancer cells
2026Open Access
TCR-engineered T cells targeting a shared β-catenin mutation eradicate solid tumors
Nature Immunology·2025· 2 citedOpen Access
Targeting the roots of myeloid malignancies with T cell receptors
Nature reviews. Cancer·2025· 2 cited
Precision T cell correction platform for inborn errors of immunity
Molecular Therapy·2025· 1 citedOpen Access
Selection of therapeutically effective T-cell receptors from the diverse tumor-bearing repertoire
Journal for ImmunoTherapy of Cancer·2025· 2 citedOpen Access
Translation dysregulation in cancer as a source for targetable antigens
Cancer Cell·2025· 14 citedOpen Access
Adoptive T cell therapy targeting an inducible and broadly shared product of aberrant mRNA translation
Immunity·2025· 7 citedOpen Access
An adjusted droplet digital PCR assay for quantification of vector copy number in CAR-T cell and TCR-T cell products
Immuno-Oncology Technology·2024· 1 citedOpen Access
Non-viral vectors for chimeric antigen receptor immunotherapy
Nature Reviews Methods Primers·2024· 10 cited
T cell correction pipeline for Inborn Errors of Immunity
2024· 1 citedOpen Access
Diversity of intratumoral regulatory T cells in B-cell non-Hodgkin lymphoma
Blood Advances·2023· 24 citedOpen Access
A T cell receptor targeting a recurrent driver mutation in FLT3 mediates elimination of primary human acute myeloid leukemia in vivo
Nature Cancer·2023· 34 citedOpen Access
A systematic safety pipeline for selection of T-cell receptors to enter clinical use
npj Vaccines·2023· 18 citedOpen Access
PB2501: INSIGHT-1: A PHASE I FIRST-IN-HUMAN TCR TRIAL OF GENETICALLY MODIFIED T-CELLS TARGETING TDT IN CHILDREN AND ADULTS WITH T- AND B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA/LYMPHOMA (TRIAL-IN-PROGRESS)
HemaSphere·2023Open Access
DIVERSITY OF INTRATUMORAL REGULATORY T CELLS IN B‐CELL NON‐HODGKIN LYMPHOMA
Hematological Oncology·2023Open Access
Supplementary Video 1 from Intrinsic Functional Potential of NK-Cell Subsets Constrains Retargeting Driven by Chimeric Antigen Receptors
2023Open Access
Data from Intrinsic Functional Potential of NK-Cell Subsets Constrains Retargeting Driven by Chimeric Antigen Receptors
2023Open Access
Data from Intrinsic Functional Potential of NK-Cell Subsets Constrains Retargeting Driven by Chimeric Antigen Receptors
2023Open Access
Supplementary Video 1 from Intrinsic Functional Potential of NK-Cell Subsets Constrains Retargeting Driven by Chimeric Antigen Receptors
2023Open Access
Prevalent and immunodominant CD8 T cell epitopes are conserved in SARS-CoV-2 variants
Cell Reports·2023· 41 citedOpen Access
page 1 of 5Next →

Frequent Co-authors

Fridtjof Lund‐Johansen(23), Weiwen Yang(13), Leon W.M.M. Terstappen(8), Sébastien Wälchli(6), Erlend Strønen(5), Ton N. Schumacher(5), Morten M. Nielsen(5), Arne Kolstad(5), Graça Almeida‐Porada(4), Mireille Toebes(4), Maarja Laos(4), Shraddha Kumari(4), Ravi Chand Bollineni(4), Trung Tran(4), Jorunn N. Johansen(3), Muhammad Ali(3), Zsófia Földvári(3), Eirini Giannakopoulou(3), Václav Hořejšı́(3), Halvor Rollag(3)